Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | XDH | P47989 | 2/20 | 0.46 |
| ▸ | GCGR | P47871 | 12/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.46 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.46 |
| ▸ | GIPR | P48546 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13800053 | 0.86 | LMNA (0.50) | LMNAXDHGCGREPHX2NR1H4 | |
| SCHEMBL4085756 | 0.81 | L3MBTL1 (0.56) | LMNAGCGR | |
| SCHEMBL2658910 | 0.79 | NR1H4 (0.58) | LMNAGCGREPHX2NR1H4GIPR | |
| SCHEMBL4081943 | 0.79 | XDH (0.55) | LMNAXDHGCGR | |
| Hydrochloric Acid SCHEMBL4092773 | 0.78 | NR1H4 (0.57) | LMNAGCGREPHX2NR1H4GIPR | |
| SCHEMBL4081864 | 0.77 | HDAC1 (0.60) | LMNAGCGRGIPR | |
| SCHEMBL2665699 | 0.76 | HTT (0.49) | LMNAXDHEPHX2NR1H4PANK3 | |
| SCHEMBL2659032 | 0.76 | LMNA (0.53) | LMNAXDH | |
| SCHEMBL13800055 | 0.76 | GCGR (0.50) | LMNAGCGRGIPR | |
| SCHEMBL13800529 | 0.76 | GCGR (0.46) | LMNAGCGRGIPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | NOVO NORDISK A/S (DK) | 2009-06-04 | — | — | US | disclosed |
| WO-2000069810-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | GLP1R, GPR119, GCGR | LMNA 3643/4885XDH 2778/4885GCGR 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.